VistaGen Therapeutics VTGN 深 沪
已收盘 12-19 16:00:00 美东时间
0.7778
+0.038
+5.11%
华盛通- 最 高0.7801
- 今 开0.70
- 成交量 746.42万股
- 最 低 0.6751
- 昨 收 0.74
- 总市值 2386.33万
- 52周最高 5.14
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 0.6751
- 委 比 -71.43%
- 总股本 3068.05万
- 历史最高 495.00
- 量 比 0.43
- 振 幅 14.19%
- 历史最低 0.6751
- 每 手 1
- 风险率 0.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
Jefferies Downgrades Vistagen Therapeutics to Hold, Lowers Price Target to $0.9
Jefferies analyst Andrew Tsai downgrades Vistagen Therapeutics (NASDAQ:VTGN) from Buy to Hold and lowers the price target from $15 to $0.9.
12-18 04:36
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Agape ATP (NASDAQ:ATPC) stock rose 68.1% to $0.15 during Wednesday's r...
12-18 01:06
Vistagen Says PALISADE-3 Phase 3 Study Of Intranasal Fasedienol For Acute Treatment Of Social Anxiety Disorder Did Not Demonstrate Statistically Significant Improvement On Primary Endpoint Of Change On SUDS
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placeboFavorable safety and tolerability data were consistent with
12-17 21:39
VistaGen appoints Nick Tressler as CFO
Vistagen (VTGN) on Monday announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective December 1, 2025. Most recently, he served as CFO of DYNEX Technologies, and before th...
12-01 21:45
Vistagen Presents Data Showing PH80's Potential As Rapid Intranasal Treatment For Menopause Hot Flashes, At The Menopause Society 2025 Annual Meeting
Research supports the product candidate's non-hormonal, non-systemic, rapidly-acting effects on autonomic biomarkersVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with
11-26 21:37
电话会总结 ｜ Vistagen(VTGN)2026财年Q2业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据VistaGen业绩会实录，我需要指出该公司主要专注于临床试验进展汇报，财务信息披露相对有限。以下是可获得的财务信息摘要： ## 1. 财务业绩：- **现金及现金等价物**：截至2025年9月30日，公司持有7,720万美元的现金、现金等价物和有价证券 - **营收情况**：业绩会实录中未披露具体营收数据 - **利润指标**：未披露净利润、毛利率等盈利指标 - **现金流**：未披露经营性现金流、自由现金流等具体数据 ## 2. 财务指标变化：- **同比/环比变化**：业绩会实录中未提供现金头寸的同比或环比变化数据 - **GAAP/non
11-15 12:01
VistaGen Therapeutics Q2 EPS $(0.54) Misses $(0.48) Estimate, Sales $258.000K Beat $243.333K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 13.45 percent. This is a 28.57 percent decrease over losses of $(0.42) per
11-14 05:32
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
Examining the Future: VistaGen Therapeutics's Earnings Outlook
VistaGen Therapeutics (NASDAQ:VTGN) is preparing to release its quarterly earni...
11-13 02:03
